Amlodipine/valsartan

Amlodipine/valsartan
Combination of
AmlodipineCalcium channel blocker
ValsartanAngiotensin II receptor antagonist
Clinical data
Trade namesExforge, Copalia, Dafiro
AHFS/Drugs.comProfessional Drug Facts
License data
Pregnancy
category
  • AU: D
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
KEGG
CompTox Dashboard (EPA)
  (verify)

Amlodipine/valsartan, sold under the brand name Exforge among others, is a blood pressure lowering combination drug. It contains amlodipine, as the besilate, a dihydropyridine-type calcium channel blocker, and valsartan, an angiotensin II receptor antagonist. This combination is usually well tolerated and effective for the reduction of blood pressure.

The combination was approved for medical use in the European Union in January 2007, and in the United States in June 2007.

The combination is also available with hydrochlorothiazide. It was approved for medical use in the United States in April 2009, and in the European Union in November 2009. The combination of amlodipine/valsartan with hydrochlorothiazide is on the World Health Organization's List of Essential Medicines.

References

  1. ↑ "Amlodipine / valsartan (Exforge) Use During Pregnancy". Drugs.com. 11 July 2019. Retrieved 13 February 2020.
  2. ↑ "Exforge- amlodipine besylate and valsartan tablet, film coated". DailyMed. 12 June 2019. Retrieved 12 February 2020.
  3. 1 2 "Exforge EPAR". European Medicines Agency (EMA). 17 January 2007. Retrieved 26 August 2024.
  4. ↑ "Copalia EPAR". European Medicines Agency (EMA). 16 January 2007. Retrieved 26 August 2024.
  5. ↑ "Dafiro EPAR". European Medicines Agency (EMA). 16 January 2007. Retrieved 26 August 2024.
  6. ↑ "Valsartan Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
  7. ↑ Eckert S, Freytag SB, Müller A, Klebs SH (September 2013). "Meta-analysis of three observational studies of amlodipine/valsartan in hypertensive patients with additional risk factors". Blood Pressure. 22 (sup1): 11–21. doi:10.3109/08037051.2013.793891. PMID 23713686. S2CID 25814898.
  8. ↑ "Drug Approval Package: Exforge (amlodipine and valsartan) NDA #021990". U.S. Food and Drug Administration (FDA). 3 October 2008. Retrieved 19 September 2021.
  9. ↑ "Exforge HCT- amlodipine valsartan and hydrochlorothiazide tablet, film coated". DailyMed. Retrieved 12 February 2020.
  10. ↑ "Amlodipine, Valsartan, and Hydrochlorothiazide". Drugs.com.
  11. ↑ "Drug Approval Package: Exforge HCT (Amlodipine, Valsartan, Hydrochlorothiazide) Tablets NDA #022314". U.S. Food and Drug Administration (FDA). 2 September 2009. Archived from the original on 13 February 2017. Retrieved 19 September 2021.
  12. ↑ "Exforge HCT EPAR". European Medicines Agency (EMA). 16 October 2009. Retrieved 26 August 2024.
  13. ↑ "Copalia HCT EPAR". European Medicines Agency (EMA). 4 November 2009. Retrieved 26 August 2024.
  14. ↑ "Dafiro HCT EPAR". European Medicines Agency (EMA). 4 November 2009. Retrieved 26 August 2024.
  15. ↑ The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th list. Geneva: World Health Organization. 2025. hdl:10665/382243.